The updated COVID-19 shots were approved on August 27 and 28, 2026, and they started shipping the same week. If you went looking for one last fall and got turned around at the pharmacy counter, or told to come back with something in writing from your physician, this post is mostly for you.

Here is what is out, who can get it, what counts as high risk, and what the virus is doing right now.

What was approved, and when you can actually get it

FDA cleared XFG-adapted formulas from all three manufacturers. Pfizer-BioNTech’s Comirnaty was approved August 27 (1). Moderna’s Spikevax and mNexspike followed (2). Novavax announced its Nuvaxovid approval on August 28, alongside clearances in the EU and Japan (3). XFG is a recombinant in the JN.1 family, and it replaces last season’s LP.8.1 formula (4).

Now the part I get asked about most, and the part I cannot give you: there is no state-by-state rollout calendar. No health department publishes a date on which residents of that state become eligible, because distribution is commercial rather than federally allocated. Manufacturers ship to distributors, distributors ship to chains and clinics, and stock arrives store by store over days to a few weeks. Your pharmacy may have doses Tuesday while the one four miles down the road is waiting on Thursday’s truck.

So do not wait for an announcement. Set an alert on your pharmacy’s scheduling page, or call and ask when their first shipment lands.

Where the virus is right now

I want to be careful here, because the headlines and the data are telling slightly different stories.

CDC’s wastewater program is the most reliable read we have. For the week ending August 22, 2026, the national wastewater viral activity level for SARS-CoV-2 was 2.14, which CDC classifies as Very Low (5). That same number sat at 1.00 through most of July. It has roughly doubled in six weeks while staying inside the lowest category. So yes, transmission is climbing on the usual back-to-school schedule. No, we are not in a surge yet.

The regional picture is lopsided. The South is currently the highest region at 3.34. Texas is the real outlier at 11.76 across 40 reporting sites, the only state sitting in the Very High band. Mississippi reads 8.92 and South Carolina 7.47, but both are flagged for limited coverage, with two and three reporting sites respectively, so treat those as a signal rather than a measurement. Hawaii is at 7.26 across ten sites. Then Nevada 6.01, California 5.87 across 79 sites, West Virginia 5.61, Louisiana 5.31, and Florida 5.30 (6).

The variant names have shuffled again. Over the four weeks ending August 1, 2026, the two most common in CDC’s sequencing were SW.2 at about 21 percent and XFG.1.1 at about 16 percent (7). XFG.1.1 belongs to a family. Count its close relatives together and the XFG group accounts for roughly 35 percent of what is going around, which is why FDA picked XFG as this year’s vaccine target. NB.1.8.1, the one the press nicknamed Nimbus last summer, has faded to about 4 percent. BA.3.2 sits near 2 percent.

Here is the caveat, and most coverage skips it. Those percentages rest on a very small number of samples. CDC flags all eighteen of the lineages it reported for that period as based on fewer than ten sequenced specimens, or unreliable for other statistical reasons (7). In February the agency could name more than two hundred lineages circulating in the country. This month it could name eighteen. Genetic sequencing of the virus has dropped off sharply, so the variant list is a rough sketch rather than a headcount.

Which is why I put more weight on the wastewater curve than on the variant percentages right now. Genomics tells you the flavor. Wastewater tells you the size.

The page to bookmark

CDC posts wastewater viral activity by state here, and it is updated every Friday with the previous week’s numbers:

https://www.cdc.gov/wastewater/respiratory-viruses/state.html

It covers influenza A, SARS-CoV-2 b (Covid-19), and RSV on the same page, so you can see which of the three is actually moving in your area before you decide whether that sore throat needs a test. If you want the county-level view alongside emergency department visit data, CDC’s Respiratory Illnesses Data Channel has a search box for your state or county:

https://www.cdc.gov/respiratory-viruses/data/index.html

Bookmark the first one. It answers the question patients are really asking, which is not “how bad is COVID nationally” but “is there anything going around here.”

Who the FDA says can get it

The licensed indications are narrower than they were before 2025, and they differ slightly by product:

• Comirnaty (Pfizer-BioNTech), mRNA: ages 65 and older, or ages 5 through 64 with at least one condition that raises the risk of severe COVID-19 (1)
• Spikevax (Moderna), mRNA: ages 65 and older, or 6 months through 64 with at least one such condition (2)
• mNexspike (Moderna), mRNA: ages 65 and older, or 12 through 64 with at least one such condition (2)
• Nuvaxovid (Novavax), protein-based rather than mRNA: ages 65 and older, or 12 through 64 with at least one such condition (3)

CDC’s own recommendation, unchanged since the September 2025 ACIP vote, covers everyone 6 months and older under individual-based decision-making (8). So the federal recommendation is broader than the federal license. That gap is exactly where the confusion at the pharmacy counter lives, and nobody at either agency has resolved it for you.

The high-risk list is longer than you think

Most people badly underestimate how wide this list is. CDC’s conditions, in alphabetical order rather than order of risk: cancer, cerebrovascular disease, chronic kidney disease at any stage, chronic liver disease, chronic lung disease including asthma, cystic fibrosis, dementia and other neurologic conditions, type 1 or type 2 diabetes, disabilities, heart conditions, hemoglobin blood disorders, HIV, an immunocompromising condition, mental health conditions, overweight and obesity, physical inactivity, pregnancy, current or former smoking, solid organ or stem cell transplant, substance use disorders, and tuberculosis (9).

Read the back half of that again. Overweight is defined as a BMI of 25 or higher (9). About 72 percent of American adults age 20 and over fall at or above that line, combining the 31.7 percent who are overweight with the 40.3 percent who have obesity (10). Current smoking counts, and so does former smoking. So does physical inactivity. So does depression.

Here is my opinion, and I hold it firmly. A criteria list that broad is not functioning as a clinical gate. It is functioning as paperwork. If you are an adult in the United States, the odds are strong that you already qualify under a criterion you would not have thought to claim, and the honest thing for the system to do would be to say so out loud instead of making each person audit themselves at a kiosk.

Do you need a note from your doctor?

Short answer: almost certainly not, and you should not assume you do.

On September 19, 2025, ACIP voted to recommend COVID-19 vaccination for everyone 6 months and older through individual-based decision-making. In the same meeting it took up a proposal that would have let jurisdictions require a prescription, and that proposal failed on a tiebreaker cast by the committee chair (8, 11). CDC’s position is that the required conversation can happen with a pharmacist, a nurse practitioner, or a PA standing right there at the counter. No written order from your physician.

What tripped people up last fall was state law rather than federal policy. Several states had written pharmacist vaccination authority so that it tracked ACIP’s recommendation language directly, and when that language narrowed, pharmacists in those states abruptly lost standing authority to vaccinate without a prescription. By late September 2025, 26 states had issued standing orders or executive actions restoring broader access (12). The rest had not, and store-level policy varied inside states that had.

Two phone calls save you an afternoon. Call the pharmacy, ask whether they need a prescription for someone your age and situation, and ask whether the 2026-2027 formula is physically on their shelf yet. Then call the number on the back of your insurance card and ask what your plan covers this season. Your state health department’s immunization page is worth two minutes as well, since that is where a new standing order would appear first.

And if a pharmacy does turn you away for want of an order, that is a five-minute problem for your physician to solve, not a reason to abandon the shot. Call the office. Do not walk out and let it go until spring.

Why I think the restrictions backfire

Because the numbers are already bad, and friction is the best explanation for them.

Only 17.5 percent of American adults received the 2025-2026 COVID vaccine, measured at the close of the season in February 2026 across a survey sample of roughly 197,000 people (13). Among adults 65 and older, the group with the clearest, least-debatable benefit, coverage reached 33.5 percent (13). Two-thirds of the highest-risk group in the country did not get vaccinated.

I do not believe most of that gap is ideological. Some of it is. Most of it is drag. Every additional step you insert between a mildly willing person and a needle removes some of them, and the removal is silent. An eligibility attestation form removes a few. A phone call to confirm the pharmacy will actually do it removes a few more. An uncertain bill removes more still. None of those people write a letter explaining why they gave up. They just do not come.

There is a second cost that gets less attention. When the government tells healthy adults they no longer qualify, the message the public hears is that the shot is not worth much. That message does not stay inside its intended audience. It reaches the 68-year-old with COPD who did qualify, who now assumes the whole thing has been downgraded, and who skips it.

If you decided back in 2021 or 2022 that two doses were enough and you have not thought about it since, I would ask you to reconsider on narrow, unromantic grounds. Not because the pandemic is back. Because protection fades, this year’s formula is matched to what is circulating now, and the downside of a sore arm for two days is very small next to a week of illness you did not need to have.

Has the virus changed?

Not in the way people fear. Severity has not meaningfully increased. WHO and ECDC have continued to rate the currently circulating variants as low risk for severe outcomes, and the mutations driving the current lineages are the immune-evasion kind rather than the tissue-damage kind. Laboratory work on XFG published in 2025 found roughly a two-fold drop in neutralizing antibody effectiveness compared with the then-dominant lineage, which explains reinfection without implying worse disease (14).

Symptoms are the familiar Omicron picture. Sore throat, often genuinely severe. Hoarseness. Congestion, cough, fatigue, headache, body aches, and sometimes nausea or loose stools. Loss of smell is far less common than it was in 2020. The “razor blade throat” description that attached itself to NB.1.8.1 in 2025 has stuck around in press coverage, and it is a real complaint, though it is also just a bad Omicron sore throat rather than a diagnostic sign.

What to monitor: shortness of breath at rest or on minimal exertion, chest pain, confusion or unusual difficulty staying awake, bluish lips, and an inability to keep fluids down. Watch for the pattern where someone improves for several days and then clearly worsens around day seven to ten. If you own a fingertip pulse oximeter, a resting reading that keeps coming back at 94 percent or below deserves a same-day call, not a wait-and-see.

Treatment still exists and is still underused. Nirmatrelvir-ritonavir has to be started within five days of symptom onset in adults at high risk of progression, which as we established covers a very large share of adults (15). Day six is too late. If you are in a risk category, know before you are sick how you would reach a clinician quickly.

How long do you stay home?

CDC no longer has a five-day isolation rule, and has not since 2024. The current guidance is symptom-based. Stay home and away from others while you are sick. You can return to normal activities once both of the following have been true for at least 24 hours: your symptoms are improving overall, and you have had no fever without using fever-reducing medication (16).

Then take added precautions for the next five days. Mask well, keep some distance, improve ventilation, and test before you spend time around anyone vulnerable. If a fever returns or you get worse after going back out, go home again and restart the same clock (16).

On work: CDC does not recommend a fixed number of days off, and there is no federal number for your employer to enforce. Your workplace policy is its own creature, and so is your child’s school district. If HR asks for a return-to-work note, that is a workplace requirement rather than a public health one, and it is worth saying so plainly when you ask your physician for it. Healthcare workers and staff in long-term care facilities are the exception and should follow their facility’s occupational health rules instead.

What else lowers your risk

The vaccine is the biggest lever. Metabolic health is the second one, and it is the one you have some control over between now and January.

CDC’s own analysis of 148,494 adults treated at 238 US hospitals found risk of COVID-19 hospitalization was lowest at a BMI of 24.2, ICU admission lowest at 25.9, and death lowest at 23.7, with risk climbing sharply above those points (17). That is a dose-response curve, not a threshold effect, which means movement in the right direction counts even if you do not reach a target number.

Two other findings are worth putting side by side, because together they say something more useful than either does alone.

In a Scottish study of 3.6 million people, vaccinated adults with a BMI over 40 were 76 percent more likely to be hospitalized or die from COVID-19 than vaccinated adults at a normal BMI (adjusted rate ratio 1.76, 95% CI 1.60 to 1.94). In the prospective arm of the same work, 55 percent of people with severe obesity had unquantifiable neutralizing antibody titers six months after their second dose, compared with 12 percent of people at a normal BMI. A third dose restored neutralizing capacity, and then it declined faster again (18).

Meanwhile, in a cohort of 9.17 million adults in England, protection against hospitalization two weeks after the second dose was essentially identical across BMI categories, with an odds ratio of 0.32 in people with obesity against 0.34 in people at a healthy weight. Protection against death was actually stronger in the obesity group, 0.26 against 0.39 (19).

Put those together and the conclusion is not the one people expect. The vaccine works in people with obesity. Its protection simply fades faster. That is an argument for getting the seasonal dose rather than skipping it, and it is the single clearest reason I push seasonal vaccination hardest in my obesity medicine patients.

If you are working on weight for metabolic reasons, this belongs on the list of reasons alongside the ones you already know. I have written about the current medication options in New Weight Loss Pills Foundayo and Wegovy Explained, and about what sustains loss over years in Doctor Supervised Weight Loss: What Works Long Term. For the version of this discussion from last season, including how the eligibility fight started, see 2025 COVID-19 Vaccine: Eligibility, Prescriptions, and Debate.

Two smaller things. You can get the COVID vaccine and the flu vaccine at the same visit, one in each arm, and doing so is the single easiest way to make sure both actually happen (20). And CDC’s risk list includes physical inactivity as its own line item, which is a quiet reminder that the walk you keep meaning to start is doing more than one job.

For patients

Check the wastewater page for your state before you decide how careful to be this month. Call your pharmacy, ask about stock and about whether they need a prescription where you live, and book the appointment while you are on the phone. If you are 65 or older, or you have any condition on that list, do not let a form at the counter end the attempt. If you have been waiting since your first two doses in 2021, this is a reasonable year to restart.

For colleagues

Three practical notes. First, expect the FDA-license-versus-CDC-recommendation gap to generate pharmacy callbacks again this fall, and consider building a standing message your staff can send rather than routing each one to you. Second, screen for eligibility criteria your patients will not volunteer: former smoking status, physical inactivity, and a documented mental health condition all qualify under the CDC list and are all commonly missing from problem lists. Third, if you practice by video as I do, the eligibility conversation is straightforward to complete in a visit that is already happening for something else, and it takes about ninety seconds.

The Bottom Line

The 2026-2027 vaccines are approved, matched to XFG, and shipping now. There is no statewide rollout date to wait for, so call your pharmacy. You very likely qualify under criteria broader than you assume, and you almost certainly do not need a note from me or anyone else, though it is worth one phone call to confirm before you drive over. COVID activity is low nationally and rising, with Texas and the South well ahead of everyone else. And if you stopped after your first two doses because the emergency ended, the case for one more is quiet and practical rather than dramatic: your protection has faded, this formula matches what is going around, and the shot is easier to get than the illness is to sit through.

Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.

Sources

1. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine. August 27, 2026. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-approval-xfg-adapted
2. Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines. August 2026. https://www.biospace.com/press-releases/moderna-receives-u-s-fda-approval-for-updated-2026-2027-covid-19-vaccines
3. Novavax’s Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid Approvals in the U.S., EU and Japan for the 2026-2027 Vaccination Season. August 28, 2026. https://www.biospace.com/press-releases/novavaxs-partnership-strategy-continues-to-deliver-with-xfg-adapted-nuvaxovid-approvals-in-the-u-s-eu-and-japan-for-2026-2027-vaccination-season
4. U.S. Food and Drug Administration. COVID-19 Vaccines (2026-2027 Formula) for Use in the United States Beginning in Fall 2026. https://www.fda.gov/vaccines-blood-biologics/industry-biologics/covid-19-vaccines-2026-2027-formula-use-united-states-beginning-fall-2026
5. CDC. National Wastewater Data for Respiratory Viruses. Data for the week ending August 22, 2026; updated August 27, 2026. https://www.cdc.gov/wastewater/respiratory-viruses/national.html
6. CDC. State and Territory Wastewater Data for Respiratory Viruses. Data for the week ending August 22, 2026. https://www.cdc.gov/wastewater/respiratory-viruses/state.html
7. CDC. SARS-CoV-2 Variant Proportions. National estimates, four-week period ending August 1, 2026; published August 28, 2026. https://data.cdc.gov/Laboratory-Surveillance/SARS-CoV-2-Variant-Proportions/jr58-6ysp
8. U.S. Department of Health and Human Services. ACIP Recommends COVID-19 Immunization Based on Individual Decision-making. September 19, 2025. https://www.hhs.gov/press-room/acip-recommends-covid19-vaccination-individual-decision-making.html
9. CDC. People with Certain Medical Conditions and COVID-19 Risk Factors. https://www.cdc.gov/covid/risk-factors/index.html
10. National Center for Health Statistics. Prevalence of Overweight, Obesity, and Severe Obesity Among Adults Age 20 and Older: United States, 1960-1962 Through August 2021-August 2023. https://www.ncbi.nlm.nih.gov/books/NBK621182/
11. CDC advisers vote that patients must consult a health care provider for Covid-19 vaccination, but no prescription required. CNN, September 19, 2025. https://www.cnn.com/2025/09/19/health/cdc-acip-hepatitis-mmrv-covid-vaccine
12. Kates J, Bell C, Michaud J, Williams E, Tolbert J. Tracking State Actions on Vaccine Policy and Access. KFF, September 24, 2025. https://www.kff.org/state-health-policy-data/tracking-state-actions-on-vaccine-policy-and-access/
13. CDC. COVID-19 Vaccination Coverage, Overall and by Selected Demographics and Jurisdiction, Among Adults 18 Years and Older, by Season. National Immunization Survey-Fall Respiratory Virus Module, week ending February 21, 2026. https://data.cdc.gov/d/ksfb-ug5d
14. Gavi. Eight things you need to know about the new “Nimbus” and “Stratus” COVID-19 variants. June 16, 2025. https://www.gavi.org/vaccineswork/eight-things-you-need-know-about-new-nimbus-and-stratus-covid-variants
15. U.S. Food and Drug Administration. PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers. https://www.fda.gov/media/158165/download
16. CDC. Preventing Spread of Respiratory Viruses When You’re Sick. https://www.cdc.gov/respiratory-viruses/prevention/precautions-when-sick.html
17. Kompaniyets L, Goodman AB, Belay B, et al. Body Mass Index and Risk for COVID-19-Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death, United States, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021;70(10):355-361. PMID 33705371. https://pubmed.ncbi.nlm.nih.gov/33705371/
18. van der Klaauw AA, Horner EC, Pereyra-Gerber P, et al. Accelerated waning of the humoral response to COVID-19 vaccines in obesity. Nat Med. 2023;29(5):1146-1154. PMID 37169862. https://www.nature.com/articles/s41591-023-02343-2
19. Piernas C, Patone M, Astbury NM, et al. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2022;10(8):571-580. PMID 35780805. https://doi.org/10.1016/S2213-8587(22)00158-9
20. CDC. Staying Up to Date with COVID-19 Vaccines. https://www.cdc.gov/covid/vaccines/stay-up-to-date.html